Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Dr James Davies and Dr Lynn Quek, who have both been awarded MRC Clinician Scientist Fellowships.

Dr Lynn QuekDr Quek, who works with Prof Paresh Vyas (MRC Molecular Haematology Unit), will study the ‘Epigenomic Mechanisms of Action of Novel Mutant Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukaemia’. Acute Myeloid Leukaemia is an aggressive adult leukaemia, fatal in most patients. It is characterised by a differentiation block on stem cells, leading to an accumulation of immature cells. In this project, Dr Quek will study the impact of a drug called Enasidenib on this process. Enasidenib inhibits the enzyme Isocitrate dehydrogenase 2 (IDH2), which is mutated in 20% of AML patients. While we know that Enasidenib can trigger cell differentiation, we are yet to fully understand how this takes place. Dr Quek will investigate the impact of Enasidenib on gene regulation, hopefully revealing new targets for drug-discovery in AML and other IDH-mutant cancers.

 

Dr James DaviesDr Davies, who works with Prof Doug Higgs (MRC Molecular Haematology Unit), will work on the 'Development of highly sensitive methods for defining off target mutations to enable safe gene editing of haematopoietic cells for transplantation’. Genome editing holds huge promise for modern medicine, particularly for blood diseases. However, the risk of unintended DNA mutations that could lead to malignancy acts as a major barrier to the clinical utility of the technique. Dr Davies will develop a technique to define 'off-target' effects and then go on to investigate the site and burden of this collateral damage, with the view of optimising genome editing for thalassemia and sickle cell disease (hereditary blood disease).

Similar stories

Focus on racism- making a difference for sickle cell disease

Project aims to increase understanding, reduce stigma, and improve the quality of life of people living with sickle cell disease.

Giulia Orlando becomes a John Goldman Fellow

Many congratulations to Dr Giulia Orlando, who has become a 2021 Leukaemia UK John Goldman Fellow.

New atlas revealed of bone marrow haematopoiesis during development

A new study published this week in Nature, provides the most detailed analysis so far of the prenatal development of blood and immune cells in the bone marrow.

Changes in blood cell production over the human lifetime may hold clues to patterns of disease

A new paper published in Cell Reports reveals that changes in the gene expression of blood stem cells occur across the human lifetime; an important step in the understanding and treatment of blood disorders.

New Associate Professor appointments announced

Congratulations to Dr Bethan Psaila, Dr Benjamin Fairfax, Dr Hashem Koohy, Dr Andrew Blackford and Dr Oliver Bannard who have all been awarded the title of Associate Professor in recognition of their research achievements, contribution to teaching and contributions to the Medical Sciences Division.

Mechanism behind repair of cancer-inducing mutations discovered

New Nature paper uncovers the precise mechanism behind how the BRCA1 protein detects and engages with DNA breaks in the genome, helping to prevent the development of breast and ovarian cancers.